27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Of the 20,660 patients who visited the ER, 1,486 patients who were transported by ambulance were included in this study. 5 key findings →
Design: cohort study Participants: 20,660 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the patients, 82.2% were receiving at least one dizziness-associated medication and 71.2% at least one hypotension-associated medication. 5 key findings →
Design: cohort study Participants: 210 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 2889 patients with delirium (mean age 85 years; 54.7% female), 59.8% were triaged at SETS 1–2 (high priority) and 40.2% at SETS 3–4 (low priority). 5 key findings →
Design: cohort study Participants: 2,889 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In contrast, patients with LB pathology alone, in the absence of AD biomarker positivity, had less overall cognitive impairment but more focal dysexecutive and visuospatial deficits. 5 key findings →
Design: longitudinal study Participants: 85 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We included 17098 records, 4139 from deceased individuals (mean age 81) and 12959 from living individuals (mean age 79). 4 key findings →
Design: case-control study Participants: 17,098 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 40,074 inpatient encounters (median age 72 years [IQR 62-82], 46.9% male, 22.7% Black, 4.6% Hispanic), the most common serious illness was heart failure (66.0%), followed by COPD (39.3%), kidney failure (12.4%), cancer (12.3%), and dementia (11.6%). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The final model, which included age, systolic blood pressure >140, atrial fibrillation, and tobacco use, achieved an AUC of 0.83 (95% CI 0.75-0.90) in the development cohort (N=143, 62.4±12.6 years, 44% female, 36% non-white race) and 0.85 (95% CI 0.77-0.92) in the validation cohort (N=127, 65.2±16.8 years, 51% female, 34% non-white race), with similar results using WMH measurements derived from cMRI (N=120, p=0.98, AUC=0.86, 95% CI 0.77-0.93). 5 key findings →
Participants: 143 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cohort 1 included 446 individuals (mean age (SD) 65.2 years (8.9); 203 women), Cohort 2 included 164 individuals (mean age (SD) 49.9 years (12.6); 88 women). 5 key findings →
Design: longitudinal study Participants: 446 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 261 patients (75.3±6.8 years) were recruited from a memory-clinic cohort. 5 key findings →
Design: cross-sectional Participants: 261 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Non-modifiable (age, apolipoprotein E (APOE) ɛ4 genotype and sex) and modifiable risk factors (co-morbidities at baseline, such as hypertension and cardiovascular disease, BMI, and sleep duration) were analyzed with mixed-effects models, adjusted for age and sex, to predict longitudinal measurements of WMH, Aβ and tau. 5 key findings →
Design: longitudinal study Participants: 494 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During the COVID-19 pandemic, home health agencies (HHAs) discharges following acute hospitalizations increased. 1 key finding →
Design: cohort study Participants: 426,766 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 4240 patients included in the analysis (mean [SD] age, 75 [7] years; 2327 [54.9%] female), 1991 were diagnosed with CRC and 2249 with NSCLC. 2 key findings →
Design: cohort study Participants: 4,240 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We have used restriction isotyping (restriction enzyme isoform genotyping) for rapid typing of common apolipoprotein E isoforms (E2, E3, E4). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinical and neuropathological criteria forfrontotemporal dementia * Early loss of insight into the fact that the altered condition is due to a pathological change of own mental state. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Traumatic brain injury (TBI), a major cause of persistent cognitive impairment (CI), increases the long-term risk of developing dementia, including Alzheimer's disease (AD). 3 key findings →
Design: longitudinal study Participants: 29 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This systematic review aims to elucidate the neuropathological basis of the HIDA and psychosis domains, exploring whether distinct proteinopathies and neural circuit dysfunctions are associated with these symptoms. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MAF supplementation improved cognitive function, especially after 6 months, in elderly people undergoing rehabilitation. 4 key findings →
Design: randomized controlled trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From the 144 participants (56.3% female and 43.7% male, with a mean [standard deviation] age of 80.7 [7.7] years), 118 participants were available for final follow-up. 4 key findings →
Design: cohort study Participants: 144 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. 1 key finding →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Aging and the emergence of age-associated illnesses are one of the major challenges of our present society. 3 key findings →
Design: systematic review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most prevalent dementia in the world. 1 key finding →
Design: systematic review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Some degree of cognitive decline after surgery occurs in as many as one quarter of elderly surgical patients, and this decline is associated with increased morbidity and mortality. 3 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
DAP12 is an ITAM-containing adapter that associates with receptors in myeloid and NK cells.
Full summary, score breakdown and related studies → Original source Free full text
Triggering receptor expressed on myeloid cells 2 (TREM-2) is a membrane-bound receptor expressed by microglia and macrophages.
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →